secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0000950170-24-096627
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eliem Therapeutics Q2 net loss $54.9M; completed Tenet Medicines acquisition and $120M financing
--------------------------------------------------------------------------------

- Completed acquisition of Tenet Medicines and concurrent $120M private placement in June 2024.
- Cash and equivalents $223.1M as of June 30, expected to fund operations into 2027.
- Net loss of $54.9M for Q2 2024 vs $5.2M in Q2 2023, largely due to $51.7M acquired IP R&D expense.
- Lead product budoprutug (anti-CD19) targets autoimmune diseases including lupus and immune thrombocytopenia.
- Appointed Aoife Brennan as CEO and Jan Hillson as Senior Clinical Advisor; added to Russell 2000 index.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000095017024096627/0000950170-24-096627-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000095017024096627/elym-20240814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-096627

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer